2 news items
MAIA Biotechnology (MAIA): Pioneering New Frontiers in NSCLC Treatment with THIO
BMRN
EXEL
GMAB
7 Jun 24
(ASCO) 2024 Annual Meeting, show a remarkable overall response rate (ORR) of 38% and a disease control rate (DCR) of 85% when THIO is paired
4 Stocks to Watch in the Booming Regenerative Medicine Market
BSEM
MDXG
SNN
20 May 24
of this content. RazorPitch is responsible for the production and distribution of this content. It should be expressly understood that under no circumstances
- Prev
- 1
- Next